ZIOPHARM Oncology Inc (NASDAQ:ZIOP) CEO Laurence James Neil Cooper bought 6,440 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were purchased at an average cost of $4.68 per share, with a total value of $30,139.20. Following the completion of the acquisition, the chief executive officer now owns 1,083,731 shares in the company, valued at $5,071,861.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
ZIOPHARM Oncology Inc (ZIOP) traded down $0.25 during trading on Friday, reaching $4.30. 3,309,900 shares of the company were exchanged, compared to its average volume of 1,335,318. ZIOPHARM Oncology Inc has a 1 year low of $4.16 and a 1 year high of $7.88.
ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.13). The company had revenue of $1.60 million during the quarter, compared to analyst estimates of $1.66 million. During the same period in the prior year, the business posted ($0.11) EPS. ZIOPHARM Oncology’s revenue was up .0% compared to the same quarter last year. equities analysts expect that ZIOPHARM Oncology Inc will post -0.54 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://stocknewstimes.com/2017/11/11/laurence-james-neil-cooper-buys-6440-shares-of-ziopharm-oncology-inc-ziop-stock.html.
Institutional investors have recently added to or reduced their stakes in the stock. Canada Pension Plan Investment Board acquired a new stake in ZIOPHARM Oncology in the 2nd quarter valued at $1,010,000. Tudor Investment Corp ET AL boosted its stake in ZIOPHARM Oncology by 390.4% during the 2nd quarter. Tudor Investment Corp ET AL now owns 63,304 shares of the biotechnology company’s stock worth $394,000 after purchasing an additional 50,395 shares during the last quarter. Swiss National Bank boosted its stake in ZIOPHARM Oncology by 21.3% during the 2nd quarter. Swiss National Bank now owns 218,920 shares of the biotechnology company’s stock worth $1,362,000 after purchasing an additional 38,500 shares during the last quarter. TIAA CREF Investment Management LLC boosted its stake in ZIOPHARM Oncology by 6.8% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 350,435 shares of the biotechnology company’s stock worth $2,180,000 after purchasing an additional 22,348 shares during the last quarter. Finally, State of Wisconsin Investment Board acquired a new stake in ZIOPHARM Oncology during the 2nd quarter worth $622,000. 41.86% of the stock is currently owned by hedge funds and other institutional investors.
ZIOP has been the subject of several recent research reports. ValuEngine raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Monday, August 28th. BidaskClub cut shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. HC Wainwright reissued a “buy” rating and issued a $9.50 price target on shares of ZIOPHARM Oncology in a research note on Tuesday. Finally, Zacks Investment Research raised shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research note on Friday. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $12.58.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.